RxDoctor Payments Data

Neelantha de Silva, MD

Neurology · Fort Myers, FLNPI 1407944002

Payments from drug & device makers

$22,040in general payments, 2019–2025

Across 1,034 payments — averaging $21.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Biogen$2K
  • Novartis$2K
  • UCB, Inc.$2K
  • SK Life Science, Inc.$1K
  • EMD Serono, Inc.$1K
  • plus $12K from 54 others

What the payments were for

  • Speaking & faculty fees$940%
  • Food & beverage$21,86199%
  • Education$850%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)111$2,293
Biogen67$1,930
Novartis119$1,902
UCB, Inc.55$1,626
SK Life Science, Inc.53$1,189
EMD Serono, Inc.51$1,063
AstraZeneca(2 entities)41$962
Lundbeck LLC32$729
Supernus Pharmaceuticals, Inc.24$645
Eisai Inc.25$570
Amgen21$537
Teva Pharmaceuticals USA, Inc.25$493
Lilly USA, LLC27$485
Sanofi21$482
Pfizer24$453
Neurocrine Biosciences, Inc.19$391
Argenx US, Inc.15$387
Grifols USA, LLC16$386
Amneal Pharmaceuticals LLC22$378
Ipsen Biopharmaceuticals, Inc15$310
Avanir Pharmaceuticals, Inc.19$306
Bristol Myers Squibb14$305
MDD US Operations, LLC18$300
TG Therapeutics, Inc.14$294
Jazz Pharmaceuticals Inc.33$284
Biohaven Pharmaceutical Holding Company Ltd.13$283
Takeda Pharmaceuticals U.S.A., Inc.12$250
Genentech USA, Inc.11$234
Banner Life Sciences, LLC10$198
Kyowa Kirin, Inc.10$195
Greenwich Biosciences, Inc.4$193
CSL Behring5$156
Medtronic5$136
Acadia Pharmaceuticals Inc7$128
Johnson & Johnson8$120
Tanabe Pharma America, Inc.6$113
Neurelis, Inc.4$101
Acorda Therapeutics, Inc5$94
Abbott4$88
Otsuka America Pharmaceutical, Inc.4$87
Mallinckrodt Enterprises LLC3$84
Adamas Pharmaceuticals, Inc.4$74
Livanova USA, Inc.4$73
Catalyst Pharmaceuticals, Inc.3$71
Scilex Pharmaceuticals Inc.4$69
Amylyx Pharmaceuticals, Inc.2$66
Vertical Pharmaceuticals, LLC4$64
Octapharma USA, Inc.2$64
Mallinckrodt Hospital Products Inc.2$51
Corium, LLC2$46
Merz Pharmaceuticals, LLC1$38
Neuropace, Inc.2$38
Harmony Biosciences LLC1$33
Assertio Therapeutics, Inc.2$33
Biohaven Pharmaceuticals, Inc.2$30
Upsher-smith Laboratories LLC2$29
Alnylam Pharmaceuticals Inc.1$27
GE HealthCare1$26
E.r. Squibb & Sons, L.L.C.1$22
Akcea Therapeutics, Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,040 in reported general payments places this provider in the 75th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$197,854
Medicare patients
510
Services billed
5,203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5061$679,189
Gamunex-CImmune Globul G/Gly/Iga Avg 4641$409,771
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5036$226,408
VumerityDiroximel Fumarate15$183,186
IngrezzaValbenazine Tosylate12$100,133
XcopriCenobamate52$62,447
Emgality PenGalcanezumab-Gnlm25$16,362
BriviactBrivaracetam12$15,592
Memantine Hcl418$15,419
Ajovy AutoinjectorFremanezumab-Vfrm14$15,211
Lacosamide163$13,785
Rasagiline Mesylate28$13,089
NeuproRotigotine12$10,368
Carbidopa-Levodopa ErCarbidopa/Levodopa83$7,174
Levetiracetam161$5,692

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$250$679,18961 claims
Grifols USA, LLCGamunex-C$386$409,77141 claims
CSL BehringPrivigen$156$226,40836 claims
BiogenVumerity$1,930$183,18615 claims
Neurocrine Biosciences, Inc.Ingrezza$391$100,13312 claims
SK Life Science, Inc.Xcopri$1,189$62,44752 claims
UCB, Inc.Briviact, Neupro$1,626$25,96024 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide$378$2,51831 claims
Upsher-smith Laboratories LLCTopiramate$29$1,09282 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,434 neurology providers in Florida.

Other neurology in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →